Concepedia

Publication | Closed Access

Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus Infection in High-risk Children, Based on Long-term Epidemiologic Data From Austria

DOI

65

Citations

26

References

2011

Year

Bernhard Resch, Constanze Sommer, Mark Nuijten, Susanne Seidinger, E. Walter, Vera Schoellbauer, W Mueller
The Pediatric Infectious Disease Journal

Abstract

Our results based on nationwide long-term epidemiologic data suggest that palivizumab is cost-effective in prevention of RSV disease in high-risk infants.

References

YearCitations

Page 1